<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22210564</article-id><article-id pub-id-type="pmc">3263896</article-id><article-id pub-id-type="publisher-id">1462</article-id><article-id pub-id-type="doi">10.2337/dc11-1462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Epidemiology/Health Services Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Serum 1,5-Anhydroglucitol Concentrations Are a Reliable Index of Glycemic Control in Type 2 Diabetes With Mild or Moderate Renal Dysfunction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Won Jun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Cheol-Young</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyu-Beck</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Se Eun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rhee</surname><given-names>Eun Jung</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Won Young</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Ki Won</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Sung Woo</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><sup>1</sup>Department of Internal Medicine, Division of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</aff><aff id="aff2"><sup>2</sup>Department of Internal Medicine, Division of Nephrology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Cheol-Young Park, <email>cydoctor@chol.com</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2012</year></pub-date><volume>35</volume><issue>2</issue><fpage>281</fpage><lpage>286</lpage><history><date date-type="received"><day>3</day><month>8</month><year>2011</year></date><date date-type="accepted"><day>2</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; 2012 by the American Diabetes Association.</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="281.pdf"/><abstract><sec id="s1"><title>OBJECTIVE</title><p>To assess the relationship between 1,5-anhydroglucitol (AG) levels, which are a marker of glycemic control, and stages of chronic kidney disease (CKD).</p></sec><sec id="s2"><title>RESEARCH DESIGN AND METHODS</title><p>This was a cross-sectional study with 269 subjects with type 2 diabetes who were divided into four groups based on estimated glomerular filtration rate (eGFR) using Modification of Diet in Renal Disease (eGFR<sub>MDRD</sub>) formula: 57 in control, 111 in CKD stages 1&#x02013;2, 78 in stage 3, and 23 in stages 4&#x02013;5.</p></sec><sec id="s3"><title>RESULTS</title><p>The study groups differed significantly with respect to 1,5-AG and fasting plasma glucose (FPG), age, duration of diabetes, blood pressure, HDL, and percentage of antihypertension or antidyslipidemia medication use. Stepwise multivariate regression analyses showed that 1,5-AG levels in the control group, the CKD stages 1&#x02013;2 group, and the CKD stage 3 group could be explained by HbA<sub>1c</sub>, age, duration of diabetes, FPG, and antihypertension medication. However, eGFR<sub>MDRD</sub> was the only independent determinant of 1,5-AG levels in CKD stages 4&#x02013;5. Logarithmic transformed 1,5-AG values (ln[1,5-AG]) had significant inverse correlations with HbA<sub>1c</sub> and FPG levels for CKD stages 1&#x02013;2 and CKD stage 3 (all <italic>P</italic> &#x0003c; 0.001). However, associations between ln(1,5-AG) and HbA<sub>1c</sub> or FPG were insignificant for CKD stages 4&#x02013;5 (<italic>P</italic> = 0.274 and <italic>P</italic> = 0.080, respectively).</p></sec><sec id="s4"><title>CONCLUSIONS</title><p>This study demonstrated that 1,5-AG levels do not appear to be influenced by mild or moderate renal dysfunction, suggesting it is a reliable glycemic marker in type 2 diabetes with CKD stages 1&#x02013;3.</p></sec></abstract></article-meta></front><body><p>Strict glucose control in early stages of type 2 diabetes can result in significant clinical benefits, including reduced cardiovascular mortality (<xref ref-type="bibr" rid="B1">1</xref>) and improved renal function (<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>). Although HbA<sub>1c</sub> levels have been the main glycemic marker in the management of type 2 diabetes since the 1980s, other measures of glycemic control are available, such as glycated albumin, fructosamine, and 1,5-anhydroglucitrol (1,5-AG). Compared with HbA<sub>1c</sub>, serum 1,5-AG levels can reflect more recent glycemic control (<xref ref-type="bibr" rid="B5">5</xref>) as well as postprandial hyperglycemia (<xref ref-type="bibr" rid="B6">6</xref>).</p><p>Measuring 1,5-AG levels has several advantages, including retained metabolic inertness, steady-state levels in all tissues, and negligible influence of sampling conditions such as collection time, body weight, age, sex, and food intake of the subjects (<xref ref-type="bibr" rid="B7">7</xref>). However, 1,5-AG reabsorption is competitively inhibited in the renal proximal tubule by glucosuria and is excreted in the urine when glucose levels surpass the renal threshold for glucosuria (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>). Studies have reported that values for 1,5-AG may be influenced by several physiologic factors or diseases associated with disturbed or impaired renal function (<xref ref-type="bibr" rid="B10">10</xref>&#x02013;<xref ref-type="bibr" rid="B14">14</xref>), although these studies had small sample sizes. Little information is available on the relationship between 1,5-AG levels and the mild or moderate renal dysfunction commonly found in subjects with type 2 diabetes. Therefore, this study assessed the effects of renal function on the glycemic marker 1,5-AG in type 2 diabetes using classification by chronic kidney disease (CKD) stage.</p><sec id="s5"><title>RESEARCH DESIGN AND METHODS</title><sec id="s6"><title>Subjects and study design</title><p>A cross-sectional study was conducted involving individuals with type 2 diabetes who had serum creatinine and spot urine analyses during at least two visits over 3 months and who had 1,5-AG levels available at the Department of Endocrinology and Metabolism of Kangbuk Samsung Hospital in Korea between 2008 and 2010.</p><p>The estimated glomerular filtration rate (eGFR) was calculated by using the Modification of Diet in Renal Disease (MDRD) formula: eGFR<sub>MDRD</sub> = 186 &#x000d7; serum creatinine <sup>&#x02212;1.154</sup> &#x000d7; age<sup>&#x02212;0.203</sup> &#x000d7; [0.742 if female]. In accordance with the National Kidney Foundation Disease Outcomes Quality Initiative classification system, CKD was defined on the basis of eGFR and categorized into three groups defined by the cutoff points between stages 2 and 3 as well as between stages 3 and 4. Therefore, subjects in the stages 1&#x02013;2 CKD group had eGFRs &#x02265;60 mL/min/1.73 m<sup>2</sup>, the stage 3 CKD group had eGFRs &#x0003c;60 to &#x02265;30 mL/min/1.73 m<sup>2</sup>, and the stages 4&#x02013;5 CKD group had eGFRs &#x0003c;30 mL/min/1.73 m<sup>2</sup> (<xref ref-type="bibr" rid="B15">15</xref>). Subjects with an eGFR &#x02265;90 mL/min/1.73 m<sup>2</sup> without proteinuria or history of kidney disease were placed in the control group. Consequently, 269 subjects were grouped as follows: 57 in control, 111 in CKD stages 1&#x02013;2; 78 in stage 3; and 23 in stages 4&#x02013;5. Subjects with acute renal failure, recent infection, dialysis, known renal tubular acidosis, pregnancy, type 1 diabetes (C-peptide &#x0003c;0.18 nmol/L), chronic liver disease, or malignancy were excluded. Subjects aged &#x0003c;30 years or &#x0003e;70 years were also excluded due to the small number of participants in these age categories and potential comorbidities. The protocol for this study was approved by the institutional review board at Kangbuk Samsung Hospital. Written informed consent was obtained from all subjects.</p></sec><sec id="s7"><title>Laboratory data</title><p>Levels of 1,5-AG were measured using an enzymatic assay with a two-reagent system, Determiner L 1,5-AG (Kyowa Medex, Tokyo, Japan). The assay was automated with an ADVIA 1800 Automatic Analyzer (Siemens, IL) according to the manufacturer&#x02019;s instructions. The measurement procedures, reference intervals, and coefficients of variation (CV) for 1,5-AG were based on previously published research (<xref ref-type="bibr" rid="B16">16</xref>). HbA<sub>1c</sub> levels were measured using high-performance liquid chromatography (Variant II, Bio-Rad Laboratories, Hercules, CA). The CV for glucose was &#x0003c;1.5% and the CV for HbA<sub>1c</sub> was &#x0003c;3.0%. Serum creatinine was measured using the timed end point method (Unicel DxC 800, Beckman and Coulter, Krefeld, Germany). Urinary albumin and creatinine levels were determined using the DCA 2000 urinalysis device (Bayer Corp., Elkhart, IN). Intra-assay and interassay CVs were reported as being within the range of 2&#x02013;8% for albumin/creatinine ratio. Serum insulin levels were measured using an immunoradiometric assay (Biosource, Nivells, Belgium) following the manufacturer&#x02019;s recommendations. Plasma lipids, including total cholesterol, triglycerides, and HDL and LDL cholesterol levels were measured by enzymatic colorimetric assay (Siemens, Tarrytown, NY).</p></sec><sec id="s8"><title>Statistical analyses</title><p>Data are expressed as a median with range or number (proportions). Logarithmic transformations were applied to the 1,5-AG data before analyses. Baseline characteristics according to CKD stage were compared using a Kruskal-Wallis test with post hoc analyses or a &#x003c7;<sup>2</sup> test. Skewed data, such as 1,5-AG values, were log-transformed for further analysis. Stepwise multivariate linear regression analyses were performed to identify the independent variables associated with logarithmic transformed 1,5-AG values (ln[1,5-AG]) values. To perform these analyses, demographic variables and continuous variables that were significantly different in baseline characteristics and significantly correlated with ln(1,5-AG) values in the Spearman correlations were included in the model. The model also included dummy variables, such as smoking status, and use of antihypertension and antidyslipidemia medication. Finally, the relationships between ln(1,5-AG) levels, HbA<sub>1c</sub>, and fasting plasma glucose (FPG) levels were assessed for the control group and the three CKD categories using linear regression analyses. IBM SPSS Statistics 19.0 software (IBM, Armonk, NY) was used for statistical analyses. Values of <italic>P</italic> &#x0003c; 0.05 were considered statistically significant.</p></sec></sec><sec id="s9"><title>RESULTS</title><sec id="s10"><title>Comparison of baseline clinical variables among groups according to CKD stage</title><p>Baseline demographic and clinical characteristics, laboratory values, and history of medication for participants are reported in <xref ref-type="table" rid="T1">Table 1</xref>. Duration of diabetes, serum creatinine, eGFR<sub>MDRD</sub>, and urinary albumin-to-creatinine ratio levels were significantly higher in the CKD groups than in the control, and increased with increasing CKD stage. There were significant differences in 1,5-AG and FPG levels but no significant difference in HbA<sub>1c</sub> levels among groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the subjects according to CKD stages</p></caption><graphic xlink:href="281tbl1"/></table-wrap></sec><sec id="s11"><title>Correlations among 1,5-AG, eGFR<sub>MDRD</sub>, and other clinical variables</title><p>The ln(1,5-AG) values were significantly negatively correlated with FPG and HbA<sub>1c</sub> levels, except for CKD stages 4&#x02013;5. However, 1,5-AG was not associated with serum creatinine or eGFR<sub>MDRD</sub> in a simple correlation analysis (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1462/-/DC1">Supplementary Table S1</ext-link>). Analysis of stepwise multivariate regression is reported in <xref ref-type="table" rid="T2">Table 2</xref>. For the control group and CKD stages 1&#x02013;3, HbA<sub>1c</sub> was a consistently explanatory variable of 1,5-AG. FPG, age, duration of diabetes, and medication of antihypertension were significantly associated with 1,5-AG (all <italic>P</italic> &#x0003c; 0.001, irrespective of groups and models). However, eGFR<sub>MDRD</sub> was the only independent determinant of 1,5-AG levels for CKD stages 4&#x02013;5.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Stepwise multivariate linear regression analyses as independent determinants of ln(1,5-AG) according to CKD stages</p></caption><graphic xlink:href="281tbl2"/></table-wrap></sec><sec id="s12"><title>Correlations between ln(1,5-AG) and HbA<sub>1c</sub> or FPG levels according to CKD stages</title><p><xref ref-type="fig" rid="F1">Figure 1</xref> illustrates that the inverse correlations between ln(1,5-AG) and HbA<sub>1c</sub> levels remain significant in the control (<italic>R</italic><sup>2</sup> = 0.534), CKD stages 1&#x02013;2 (<italic>R</italic><sup>2</sup> = 0.481), and CKD stage 3 (<italic>R</italic><sup>2</sup> = &#x02212;0.483) groups (all <italic>P</italic> &#x0003c; 0.001), but not for the CKD stages 4&#x02013;5 group (<italic>R</italic><sup>2</sup> = 0.057, <italic>P</italic> = 0.274; <xref ref-type="fig" rid="F1">Fig. 1</xref>). Similarly, ln(1,5-AG) is inversely correlated with FPG in the control (<italic>R</italic><sup>2</sup> = 0.414), CKD stages 1&#x02013;2 (<italic>R</italic><sup>2</sup> = 0.356) and CKD stage 3 groups (<italic>R</italic><sup>2</sup> = 0.227, all <italic>P</italic> &#x0003c; 0.001), but not for the CKD stages 4&#x02013;5 group (<italic>R</italic><sup>2</sup> = 0.145, <italic>P</italic> = 0.080; <xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Simple linear regression analyses demonstrated that 1,5-AG levels had significantly inverse correlations with HbA<sub>1c</sub> levels in normal renal function (<italic>A</italic>), in CKD stages 1&#x02013;2 (<italic>B</italic>) and 3 (<italic>C</italic>), but not in CKD stages 4&#x02013;5 (<italic>D</italic>).</p></caption><graphic xlink:href="281fig1"/></fig><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Simple linear regression analyses demonstrated that 1,5-AG levels had significantly inverse correlations with FPG levels in normal renal function (<italic>A</italic>), in CKD stages 1&#x02013;2 (<italic>B</italic>) and 3 (<italic>C</italic>), but not in CKD stages 4&#x02013;5 (<italic>D</italic>).</p></caption><graphic xlink:href="281fig2"/></fig></sec></sec><sec id="s13"><title>CONCLUSIONS</title><p>Although 1,5-AG appears to be more useful than HbA<sub>1c</sub> as a short-term marker of glycemic control and more specific in the assessment of postprandial hyperglycemia for subjects with well or moderately controlled diabetes (<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>), it has limitations for use in subjects with renal tubular acidosis, uremia, or end-stage renal disease (ESRD). However, the relationship between 1,5-AG levels and mild or moderate renal dysfunction, which is the most common stage of CKD in subjects with type 2 diabetes, is unclear.</p><p>The current study detected no relationships between 1,5-AG values and eGFR<sub>MDRD</sub> for CKD stages 1&#x02013;3 in a relatively large sample of Korean subjects with type 2 diabetes. Moreover, the associations between 1,5-AG and HbA<sub>1c</sub> or FPG levels were strongly significant in subjects with CKD stages 1&#x02013;3, but not in subjects with CKD stages 4&#x02013;5. This suggests that 1,5-AG levels reflect glycemic state and might be useful for assessing glycemic control if patients are in a state of mild or moderate renal dysfunction.</p><p>This study showed that eGFRs have influence on 1,5-AG levels not in subjects with mild or moderate renal dysfunction but in those with severe renal dysfunction or ESRD. Possible contributions of renal tubular damage to serum (or plasma) 1,5-AG levels have been shown in several case&#x02013;control reports. Some reports have claimed that 1,5-AG levels are not valid for subjects with uremia or chronic renal failure; 1,5-AG levels in these groups were as low as those in a type 2 diabetes group, significantly lower than those in healthy controls (<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>), and negatively correlated with serum creatinine (<xref ref-type="bibr" rid="B21">21</xref>). However, the numbers of study participants in these studies were small (<italic>n</italic> = 32&#x02013;75). On the other hand, a study by Yamanouchi et al. (<xref ref-type="bibr" rid="B22">22</xref>) showed that renal dysfunction has little influence on 1,5-AG concentrations. These inconsistent results might be due to group or classification discrepancies. This study was the first to analyze 1,5-AG concentrations in type 2 diabetes classified by CKD stage.</p><p>Although some have suggested that 1,5-AG levels cannot be used as a reliable index of glycemic control when subjects are in a state of renal dysfunction (<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B23">23</xref>), 1,5-AG levels in this study had significant inverse correlations with HbA<sub>1c</sub> and FPG levels when subjects had normal to moderate renal dysfunction. However, caution should be taken when using 1,5-AG values as markers of glycemic control in cases of severe renal dysfunction or ESRD. Although little information is available regarding the contribution of renal impairment to the tubular reabsorption of 1,5-AG through sodium glucose cotransporter 4 (SGLT4), a recently described candidate transporter of 1,5-AG (<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>), it may be conferred from the studies of other glucose transporters. For nephrectomized rats, expression, but not activity, of glucose transporters decreased (<xref ref-type="bibr" rid="B26">26</xref>), and glucose transporters in brush-border membranes diminished in spontaneous idiopathic Fanconi syndrome (<xref ref-type="bibr" rid="B27">27</xref>). As CKD stage or renal tubular damage progresses, it is possible that resorption of 1,5-AG would be reduced due to a decrease in SGLT4s and aggravated damage of glucose cotransporters. Until now, there were no actual data to support this hypothesis. Further understanding of the characteristics of SGLTs under renal dysfunction is needed.</p><p>FPG and 1,5-AG are correlated (<italic>r</italic> = &#x02212;0.381, <italic>P</italic> = 0.080), and this relationship is stronger than the correlation between 1,5-AG and HbA<sub>1c</sub> (<italic>r</italic> = &#x02212;0.238, <italic>P</italic> = 0.274) in subjects with CKD stages 4&#x02013;5. Emoto et al. (<xref ref-type="bibr" rid="B14">14</xref>) revealed that inverse correlations between 1,5-AG and HbA<sub>1c</sub> or FPG in diabetic patients with normal renal function were not present in patients with ESRD. However, most patients with ESRD underwent dialysis, which is known to affect 1,5-AG levels. HbA<sub>1c</sub> measurements in subjects with an aggravated CKD state could be unreliable and confounded by other factors, including shortened erythrocyte life span, blood transfusion, and accelerated erythropoiesis because of anemia and use of erythropoietin. Although it is possible that the association between 1,5-AG and HbA<sub>1c</sub> could be insignificant in the CKD stages 4&#x02013;5 group, the correlation between 1,5-AG and FPG should explored in future studies with a large sample size.</p><p>The main strengths of the present work are the relatively large study sample and the careful characterization of the participants, during which the relationships between 1,5-AG levels and eGFR<sub>MDRD</sub> or CKD stages were first evaluated. The limitations of this study are that subjects self-reported their medical history and subjects with renal tubular acidosis were included, which may have confounded the results. In addition, the number of participants with CKD stages 4&#x02013;5 was small. A sophisticated study of a large number of subjects with severe renal impairment or ESRD would help improve the understanding of the effects of renal impairment on 1,5-AG levels.</p><p>In conclusion, this study demonstrated that mild or moderate renal dysfunction appears to have no effect on serum 1,5-AG concentrations and that the relationship between 1,5-AG and glycemic markers suggests that 1,5-AG levels may be useful for monitoring glycemic control in subjects with CKD stages 1&#x02013;3.</p></sec>
      <sec sec-type="supplementary-material">
         <title>Supplementary Material</title>
         <supplementary-material id="PMC_1" content-type="local-data">
            <caption>
               <title>Supplementary Data</title>
            </caption>
            <media mimetype="text" mime-subtype="html" xlink:href="supp_35_2_281__index.html"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
                   xlink:href="supp_dc11-1462v111462_DC111462SupplementaryData.pdf"/>
         </supplementary-material>
      </sec>
   </body><back><fn-group><fn id="fn1" fn-type="supplementary-material"><p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1462/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1462/-/DC1.</ext-link></p></fn></fn-group><ack><title>Acknowledgments</title><p>No potential conflicts of interest relevant to this article were reported.</p><p>W.J.K. collected and analyzed the data and wrote the manuscript. C.-Y.P. coordinated the study, interpreted the data, contributed to discussion, and reviewed and edited the manuscript. K.-B.L., S.E.P., E.J.R., W.Y.L., K.W.O., and S.W.P. contributed to discussion and reviewed and edited the manuscript. C.-Y.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaede</surname><given-names>P</given-names></name><name><surname>Lund-Andersen</surname><given-names>H</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name></person-group> <article-title>Effect of a multifactorial intervention on mortality in type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2008</year>;<volume>358</volume>:<fpage>580</fpage>&#x02013;<lpage>591</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0706245</pub-id><pub-id pub-id-type="pmid">18256393</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovind</surname><given-names>P</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Smidt</surname><given-names>UM</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name></person-group> <article-title>Progression of diabetic nephropathy</article-title>. <source>Kidney Int</source> <year>2001</year>;<volume>59</volume>:<fpage>702</fpage>&#x02013;<lpage>709</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2001.059002702.x</pub-id><pub-id pub-id-type="pmid">11168952</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>RE</given-names></name><name><surname>Tsalamandris</surname><given-names>C</given-names></name><name><surname>Bach</surname><given-names>LA</given-names></name><etal/></person-group> <article-title>Long-term glycemic control and the rate of progression of early diabetic kidney disease</article-title>. <source>Kidney Int</source> <year>1993</year>;<volume>44</volume>:<fpage>855</fpage>&#x02013;<lpage>859</lpage><pub-id pub-id-type="doi">10.1038/ki.1993.322</pub-id><pub-id pub-id-type="pmid">8258961</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasslacher</surname><given-names>C</given-names></name><name><surname>Bostedt-Kiesel</surname><given-names>A</given-names></name><name><surname>Kempe</surname><given-names>HP</given-names></name><name><surname>Wahl</surname><given-names>P</given-names></name></person-group> <article-title>Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients</article-title>. <source>Diabetologia</source> <year>1993</year>;<volume>36</volume>:<fpage>1051</fpage>&#x02013;<lpage>1056</lpage><pub-id pub-id-type="doi">10.1007/BF02374498</pub-id><pub-id pub-id-type="pmid">8243854</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>N</given-names></name><name><surname>Tagaya</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control</article-title>. <source>Lancet</source> <year>1996</year>;<volume>347</volume>:<fpage>1514</fpage>&#x02013;<lpage>1518</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)90672-8</pub-id><pub-id pub-id-type="pmid">8684103</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dungan</surname><given-names>KM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Largay</surname><given-names>J</given-names></name><etal/></person-group> <article-title>1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes</article-title>. <source>Diabetes Care</source> <year>2006</year>;<volume>29</volume>:<fpage>1214</fpage>&#x02013;<lpage>1219</lpage><pub-id pub-id-type="doi">10.2337/dc06-1910</pub-id><pub-id pub-id-type="pmid">16731998</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dungan</surname><given-names>KM</given-names></name></person-group> <article-title>1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions</article-title>. <source>Expert Rev Mol Diagn</source> <year>2008</year>;<volume>8</volume>:<fpage>9</fpage>&#x02013;<lpage>19</lpage><pub-id pub-id-type="doi">10.1586/14737159.8.1.9</pub-id><pub-id pub-id-type="pmid">18088226</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Fukuzawa</surname><given-names>N</given-names></name><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Akanuma</surname><given-names>H</given-names></name></person-group> <article-title>Urinary excretion of 1,5-anhydro-<sc>D</sc>-glucitol accompanying glucose excretion in diabetic patients</article-title>. <source>Diabetologia</source> <year>1988</year>;<volume>31</volume>:<fpage>831</fpage>&#x02013;<lpage>835</lpage><pub-id pub-id-type="doi">10.1007/BF00277486</pub-id><pub-id pub-id-type="pmid">3234638</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Minoda</surname><given-names>S</given-names></name><name><surname>Yabuuchi</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Plasma 1,5-anhydro-<sc>D</sc>-glucitol as new clinical marker of glycemic control in NIDDM patients</article-title>. <source>Diabetes</source> <year>1989</year>;<volume>38</volume>:<fpage>723</fpage>&#x02013;<lpage>729</lpage><pub-id pub-id-type="doi">10.2337/diabetes.38.6.723</pub-id><pub-id pub-id-type="pmid">2656341</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Toyota</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus</article-title>. <source>Diabetes</source> <year>1991</year>;<volume>40</volume>:<fpage>52</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="doi">10.2337/diabetes.40.1.52</pub-id><pub-id pub-id-type="pmid">2015974</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>WH</given-names></name><name><surname>Rogers</surname><given-names>MS</given-names></name><name><surname>Lau</surname><given-names>TK</given-names></name><name><surname>Arumanayagam</surname><given-names>M</given-names></name></person-group> <article-title>The predictive value of serum 1,5-anhydro-<sc>D</sc>-glucitol in pregnancies at increased risk of gestational diabetes mellitus and gestational impaired glucose tolerance</article-title>. <source>BJOG</source> <year>2001</year>;<volume>108</volume>:<fpage>754</fpage>&#x02013;<lpage>756</lpage><pub-id pub-id-type="doi">10.1016/S0306-5456(00)00173-X</pub-id><pub-id pub-id-type="pmid">11467704</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilpatrick</surname><given-names>ES</given-names></name><name><surname>Keevilt</surname><given-names>BG</given-names></name><name><surname>Richmond</surname><given-names>KL</given-names></name><name><surname>Newland</surname><given-names>P</given-names></name><name><surname>Addison</surname><given-names>GM</given-names></name></person-group> <article-title>Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose</article-title>. <source>Diabet Med</source> <year>1999</year>;<volume>16</volume>:<fpage>496</fpage>&#x02013;<lpage>499</lpage><pub-id pub-id-type="doi">10.1046/j.1464-5491.1999.00093.x</pub-id><pub-id pub-id-type="pmid">10391398</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><name><surname>Tsutsui</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Renal tubular function affects glycosuria-related urinary excretion of 1,5-anhydroglucitol</article-title>. <source>Diabetes Care</source> <year>1999</year>;<volume>22</volume>:<fpage>863</fpage>&#x02013;<lpage>864</lpage><pub-id pub-id-type="doi">10.2337/diacare.22.5.863</pub-id><pub-id pub-id-type="pmid">10332705</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Tabata</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Nishizawa</surname><given-names>Y</given-names></name><name><surname>Morii</surname><given-names>H</given-names></name></person-group> <article-title>Plasma 1,5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes mellitus</article-title>. <source>Nephron</source> <year>1992</year>;<volume>61</volume>:<fpage>181</fpage>&#x02013;<lpage>186</lpage><pub-id pub-id-type="doi">10.1159/000186868</pub-id><pub-id pub-id-type="pmid">1630543</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><collab>National Kidney Foundation</collab> <article-title>K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title>. <source>Am J Kidney Dis</source> <year>2002</year>;<volume>39</volume>(<issue>Suppl. 1</issue>):<fpage>S1</fpage>&#x02013;<lpage>S266</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(02)70081-4</pub-id><pub-id pub-id-type="pmid">11904577</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Won</surname><given-names>JC</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><etal/></person-group> <article-title>1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source> <year>2009</year>;<volume>84</volume>:<fpage>51</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2009.01.002</pub-id><pub-id pub-id-type="pmid">19187997</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><etal/></person-group> <article-title>1,5-Anhydro-<sc>D</sc>-glucitol evaluates daily glycemic excursions in well-controlled NIDDM</article-title>. <source>Diabetes Care</source> <year>1995</year>;<volume>18</volume>:<fpage>1156</fpage>&#x02013;<lpage>1159</lpage><pub-id pub-id-type="doi">10.2337/diacare.18.8.1156</pub-id><pub-id pub-id-type="pmid">7587851</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stettler</surname><given-names>C</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Allemann</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients</article-title>. <source>Diabetes Care</source> <year>2008</year>;<volume>31</volume>:<fpage>1534</fpage>&#x02013;<lpage>1535</lpage><pub-id pub-id-type="doi">10.2337/dc08-0385</pub-id><pub-id pub-id-type="pmid">18426859</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Shouzu</surname><given-names>A</given-names></name><name><surname>Nishikawa</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Serum concentration and renal handling of 1,5-anhydro-<sc>D</sc>-glucitol in patients with chronic renal failure</article-title>. <source>Ann Clin Biochem</source> <year>1999</year>;<volume>36</volume>:<fpage>749</fpage>&#x02013;<lpage>754</lpage><pub-id pub-id-type="pmid">10586312</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Dewald</surname><given-names>L</given-names></name><name><surname>Sone</surname><given-names>J</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Kajita</surname><given-names>M</given-names></name></person-group> <article-title>Quantification of serum 1,5-anhydroglucitol in uremic and diabetic patients by liquid chromatography/mass spectrometry</article-title>. <source>Clin Chem</source> <year>1994</year>;<volume>40</volume>:<fpage>260</fpage>&#x02013;<lpage>264</lpage><pub-id pub-id-type="pmid">8313603</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Yoneyama</surname><given-names>T</given-names></name></person-group> <article-title>1,5-anhydroglucitol as a marker for the differential diagnosis of acute and chronic renal failure</article-title>. <source>Nephron</source> <year>1996</year>;<volume>73</volume>:<fpage>707</fpage>&#x02013;<lpage>709</lpage><pub-id pub-id-type="doi">10.1159/000189166</pub-id><pub-id pub-id-type="pmid">8856277</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Akanuma</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Akaoka</surname><given-names>I</given-names></name><name><surname>Akanuma</surname><given-names>Y</given-names></name></person-group> <article-title>Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients</article-title>. <source>Diabetologia</source> <year>1988</year>;<volume>31</volume>:<fpage>41</fpage>&#x02013;<lpage>45</lpage><pub-id pub-id-type="pmid">3350220</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Nagake</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><etal/></person-group> <article-title>What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis?</article-title> <source>Nippon Jinzo Gakkai Shi</source> <year>1996</year>;<volume>38</volume>:<fpage>305</fpage>&#x02013;<lpage>308</lpage><pub-id pub-id-type="pmid">8741392</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Shinohara</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>N</given-names></name><name><surname>Tachibana</surname><given-names>Y</given-names></name><name><surname>Akaoka</surname><given-names>I</given-names></name><name><surname>Miyashita</surname><given-names>H</given-names></name></person-group> <article-title>Common reabsorption system of 1,5-anhydro-<sc>D</sc>-glucitol, fructose, and mannose in rat renal tubule</article-title>. <source>Biochim Biophys Acta</source> <year>1996</year>;<volume>1291</volume>:<fpage>89</fpage>&#x02013;<lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(96)00050-5</pub-id><pub-id pub-id-type="pmid">8781530</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tazawa</surname><given-names>S</given-names></name><name><surname>Yamato</surname><given-names>T</given-names></name><name><surname>Fujikura</surname><given-names>H</given-names></name><etal/></person-group> <article-title>SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-<sc>D</sc>-glucitol, and fructose</article-title>. <source>Life Sci</source> <year>2005</year>;<volume>76</volume>:<fpage>1039</fpage>&#x02013;<lpage>1050</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2004.10.016</pub-id><pub-id pub-id-type="pmid">15607332</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Okuda</surname><given-names>M</given-names></name><name><surname>Inui</surname><given-names>K</given-names></name></person-group> <article-title>Decreased expression of glucose and peptide transporters in rat remnant kidney</article-title>. <source>Drug Metab Pharmacokinet</source> <year>2004</year>;<volume>19</volume>:<fpage>41</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="doi">10.2133/dmpk.19.41</pub-id><pub-id pub-id-type="pmid">15499168</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medow</surname><given-names>MS</given-names></name><name><surname>Reynolds</surname><given-names>R</given-names></name><name><surname>Bovee</surname><given-names>KC</given-names></name><name><surname>Segal</surname><given-names>S</given-names></name></person-group> <article-title>Proline and glucose transport by renal membranes from dogs with spontaneous idiopathic Fanconi syndrome</article-title>. <source>Proc Natl Acad Sci USA</source> <year>1981</year>;<volume>78</volume>:<fpage>7769</fpage>&#x02013;<lpage>7772</lpage><pub-id pub-id-type="doi">10.1073/pnas.78.12.7769</pub-id><pub-id pub-id-type="pmid">6950417</pub-id></mixed-citation></ref></ref-list></back></article>